中国之信(08265.HK)接获联交所复牌指引
中国之信集团(08265.HK)公布,於今年7月24日,公司收到联交所函件,当中载列有关恢复买卖股份的复牌指引,包括刊发所有尚未公布之财务业绩及处理任何审核修订;及通知市场一切重大资料,供公司股东及其他投资者评估其状况。
根据创业板上市规则,联交所可将已连续12个月暂停交易的任何证券取消上市地位。就公司之情况而言,12个月期间於明年5月17日届满。倘本公司未能於当日前处理引致其停牌之事宜和未能完全遵守创业板上市规则,使联交所满意并恢复其股份买卖,联交所上市部将建议创业板上市委员会展开取消公司上市地位之程序。
应本公司要求,公司股份自今年5月18日起已於联交所暂停买卖,并将继续暂停直至公司符合复牌指引。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.